Rhythm Pharmaceuticals (MEX:RYTM) Current Accrued Expense: MXN1,513 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
57 GF Score
Price MXN1,866.76
GF Value MXN1,964.41
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Current Accrued Expense?

Rhythm Pharmaceuticals MEX:RYTM 57 Current Accrued Expense is MXN1,513 Mil as of Jun. 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 57/100 and a GF Value™ of MXN1,964.41. The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN1,513 Mil.

Rhythm Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 (MXN1,436 Mil) to Mar. 2026 (MXN1,351 Mil) but then increased from Mar. 2026 (MXN1,351 Mil) to Jun. 2026 (MXN1,513 Mil).

Rhythm Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 (MXN727 Mil) to Dec. 2024 (MXN1,216 Mil) and increased from Dec. 2024 (MXN1,216 Mil) to Dec. 2025 (MXN1,436 Mil).

Rhythm Pharmaceuticals Current Accrued Expense Related Terms

Rhythm Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Current Accrued Expense Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 600.73 594.14 727.38 1,216.05 1,436.46

Rhythm Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,220.28 1,486.96 1,436.46 1,350.65 1,512.86
MEX:RYTM
57GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN1,513 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Current Accrued Expense of MXN1,513 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Current Accrued Expense too high?
Rhythm Pharmaceuticals' current Current Accrued Expense is MXN1,513 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Current Accrued Expense compare to MIRM and COGT?
Rhythm Pharmaceuticals' Current Accrued Expense of MXN1,513 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Current Accrued Expense is MXN1,513 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Current Accrued Expense of MXN1,513 Mil. The stock's GF Value™ is MXN1,964.41, compared to a current price of MXN1,866.76 — trading 5% below its estimated fair value. The current Current Accrued Expense is MXN1,513 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Current Accrued Expense is MXN1,513 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,866.76 is trading 5% below its estimated GF Value™ of MXN1,964.41.

Key valuation signals for MEX:RYTM:

  • Current Accrued Expense: MXN1,513 Mil
  • GF Value™: MXN1,964.41 vs. price of MXN1,866.76 (5% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
57GF Score

Get the complete analysis for MEX:RYTM

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,964.41
GF Value